Technical and Translational Development of Cardiovascular MRI (CMR)

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Background: Magnetic resonance imaging (MRI) is an important non-invasive tool to study and diagnose cardiovascular disease. MRI scanners use strong magnetic fields and radio waves to create pictures of body organs. Researchers want to find better MRI methods and new ways of imaging cardiovascular disease and better understand normal and abnormal cardiovascular and brain function. Researchers are also interested in seeing if gadolinium, the commonly used MRI contrast agent, stays in the body long after the MRI was performed.

Objectives: To develop new methods for imaging the heart and other organs of the body. To describe cardiovascular diseases using newer MRI methods To look at the relationship between cardiovascular disease and cardiovascular risk factors and other organ systems To look for gadolinium deposits in the brain from prior exams.

Eligibility: Healthy people and people with known or suspected cardiovascular disease ages 7 and older may be eligible for this study. Researchers may be particularly interested in those who: * Have suspected or known cardiovascular disease * Were previously exposed to a gadolinium-based contrast agent, * Need to have a heart MRI scheduled * Need a test of the heart or other body part or will be undergoing a future cardiac catheterization

Design: There are multiple arms to the study with optional components; therefore, there are multiple variations as to what an individual participant s experience may involve. Participants will have an MRI scan lasting up to 2 hours. The scanner is a large hollow tube. During the scan, there may be loud knocking and buzzing sounds caused by the scanner. Participants will lie on a table that slides in and out of the tube. Their vital signs may be monitored. Participants may have a test of heart electrical activity using wires connected to pads on the skin. Participants may have blood drawn. Participants may be injected with an MRI contrast agent through a plastic tube inserted in the arm.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 7
Maximum Age: 100
Healthy Volunteers: t
View:

• Age greater than or equal to 7 years

• Subjects with known or suspected cardiovascular disease

• Able to provide informed consent in writing or provide guardian consent

• Willingness to cooperate with all study procedures (including food restriction) and available for scheduled study events

• Age greater than or equal to 7 years

• Able to provide informed consent in writing or provide guardian consent

• Willingness to cooperate with all study procedures (including food restriction) and available for scheduled study events

• Known or suspected brain, hematology, oncology, endocrine, pulmonary, or other non-cardiac disease.

Locations
United States
Maryland
National Institutes of Health Clinical Center
RECRUITING
Bethesda
Contact Information
Primary
Jennifer L Henry, R.N.
henryjl@nhlbi.nih.gov
(301) 827-6720
Backup
W. Patricia Bandettini, M.D.
ingkanisorn@nih.gov
(301) 451-3128
Time Frame
Start Date: 2018-07-12
Estimated Completion Date: 2028-04-01
Participants
Target number of participants: 5000
Treatments
Assessing Gadolinium deposition within the brain in healthy and patient subjects
Both healthy subjects and patient subjects who have previously undergone MRI and received gadolinium.
Child Patient or Healthy Child
Healthy children will be used as controls for children with cardiac disease. Child patient will undergo MRI scans.
Healthy Volunteers
Subjects will be used as controls for adults with cardiac disease.
Research Patients Cardiac and Non Cardiac
Adults with cardiac disease that will undergo MRI scans.
Authors
Marcus Y Chen
Sponsors
Leads: National Heart, Lung, and Blood Institute (NHLBI)
Collaborators: National Institute of Mental Health (NIMH)

This content was sourced from clinicaltrials.gov